Akari Therapeutics (AKTX) Registration filing summary

Company overview and business model

• Incorporated in England and Wales, operates as a public company with limited liability.

• Principal executive offices located in Tampa, Florida, with a focus on biopharmaceutical development.

Management team and governance

• President and CEO is Abizer Gaslightwala, with a board including medical and financial professionals.

• Board resolutions and shareholder authorizations were obtained for recent share and warrant issuances.

Offering details and pricing

• Registration covers resale of up to 5,999,999 ADSs, representing up to 479,999,920,000 ordinary shares.

• ADSs issued or issuable from private placements and exercise of pre-funded, Series H, I, and J warrants.

• Each ADS represents 80,000 ordinary shares.

• Exercise price for warrants is $3.74 per ADS, subject to adjustment.